Related references
Note: Only part of the references are listed.Glycation increases the vascular clearance rate of IgG in mice
D. M. KENNEDY et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2010)
An improved approach for confirmatory phase III population pharmacokinetic analysis
Chuanpu Hu et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2008)
Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)
Craig L. Leonardi et al.
LANCET (2008)
Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)
Kim A. Papp et al.
LANCET (2008)
Development, cytokine profile and function of human interleukin 17-producing helper T cells
Nicholas J. Wilson et al.
NATURE IMMUNOLOGY (2007)
Pharmacokinetic drug-drug interaction potentials for therapeutic monoclonal antibodies: Reality check
Kathleen Seitz et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2007)
Molecular, biologic, and pharmacokinetic properties of monoclonal antibodies: Impact of these parameters on early clinical development
Mary Ann Mascelli et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2007)
A phase 1, double-blind, placebo-controlled study evaluating single subcutaneous administrations of a human interieukin-12/23 monoclonal antibody in subjects with plaque psoriasis
Alice B. Gottlieb et al.
CURRENT MEDICAL RESEARCH AND OPINION (2007)
A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis
Gerald G. Krueger et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
IL-23 stimulates epidermal hyperplasia via TNF and IL-20R2-dependent mechanisms with implications for psoriasis pathogenesis
Jason R. Chan et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2006)
Population-based assessments of clinical drug-drug interactions: Qualitative indices or quantitative measures?
Honghui Zhou
JOURNAL OF CLINICAL PHARMACOLOGY (2006)
Elimination mechanisms of therapeutic monoclonal antibodies
MA Tabrizi et al.
DRUG DISCOVERY TODAY (2006)
The comorbid state of psoriasis patients in a university dermatology practice
DJ Pearce et al.
JOURNAL OF DERMATOLOGICAL TREATMENT (2005)
Validation of immunoassays used to assess immunogenicity to therapeutic monoclonal antibodies
D Geng et al.
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS (2005)
Population pharmacokinetics of rituximab (anti-CD20 monoclonal antibody) in rheumatoid arthritis patients during a phase II clinical trial
CM Ng et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2005)
Medical progress - Psoriasis
MP Schon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Population pharmacokinetics of efalizumab (Humanized monoclonal anti-CD11a antibody) following long-term subcutaneous weekly dosing in psoriasis subjects
YN Sun et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2005)
Lymphatic system changes in diabetes mellitus: role of insulin and hyperglycemia
P Moriguchi et al.
DIABETES-METABOLISM RESEARCH AND REVIEWS (2005)
IL-23 drives a pathogenic T cell population that induces autoimmune inflammation
CL Langrish et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2005)
Pharmacokinetics of a human monoclonal antibody to IL-12 p40 following single intravenous infusion in patients with moderate to severe plaque-type psoriasis.
YW Zhu et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2004)
Population pharmacokinetic modeling of subcutaneously administered etanercept in patients with psoriasis
I Nestorov et al.
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS (2004)
A phase I study evaluating the safety, pharmacokinetics, and clinical response of a human IL-12 p40 antibody in subjects with plaque psoriasis
CL Kauffman et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2004)
Antibody pharmacokinetics and pharmacodynamics
ED Lobo et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2004)
Interleukin-12 and the regulation of innate resistance and adaptive immunity
G Trinchieri
NATURE REVIEWS IMMUNOLOGY (2003)
Share Paper
